Collaboration

Rani collaborates with Pegbio on oral drug delivery in obesity

Fri, 10 Jul 2026 09:00:00 -0400

Rani Therapeutics Holding Inc. has entered into a research and development collaboration with Pegbio Co. Ltd. to explore the delivery of multiple candidates from Pegbio’s obesity and metabolic disease pipeline using Rani’s proprietary Ranipill platform.

Apertura Gene Therapy enters CRADA for Niemann-Pick disease

Fri, 10 Jul 2026 09:00:00 -0400

Apertura Gene Therapy has entered into a cooperative research and development agreement (CRADA) with the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Human Genome Research Institute.

Astex Pharmaceuticals and Genentech collaborate in breast cancer

Tue, 07 Jul 2026 09:00:00 -0400

Astex Pharmaceuticals Ltd. has entered into an exclusive, worldwide research collaboration and license agreement with Genentech Inc., a member of the Roche Group, to identify small-molecule drug candidates with selective inhibitory activity as potential treatments for breast cancer.

Insilico Medicine and Takeda collaborate on drug discovery

Fri, 03 Jul 2026 09:00:00 -0400

Insilico will lead AI-driven discovery to identify molecules meeting predefined scientific and early development criteria, while Takeda will apply its global development capabilities to advance selected candidates through clinical validation.

Merck KGaA announces cardio partnership with Saturnus Bio

Thu, 25 Jun 2026 09:00:00 -0400

Merck KGaA has entered into a strategic research-stage collaboration with Saturnus Bio, a biotech founded by Versant Ventures, to establish a foundational portfolio in the field of rare genetic cardiomyopathies.

Combotope and Boehringer Ingelheim partner in cancer

Thu, 25 Jun 2026 09:00:00 -0400

Combotope Therapeutics ApS has established a strategic research collaboration with Boehringer Ingelheim Pharma GmbH & Co. KG that will leverage Combotope’s proprietary SMART-Phage platform to generate highly tumor-selective antibodies for next-generation cancer therapies.

Bioarctic and Lilly partner in neurodegeneration

Mon, 22 Jun 2026 09:00:00 -0400

Bioarctic AB has entered into a research and collaboration agreement with Eli Lilly and Co. on a new treatment in the field of neurodegeneration. The collaboration will see Bioarctic generate a new drug candidate combining its Braintransporter technology with an undisclosed Lilly molecule.

Constantiam and Cincinnati Children’s enter Gaucher collaboration

Fri, 19 Jun 2026 09:00:00 -0400

Constantiam Biosciences Inc. and Cincinnati Children’s have established a strategic collaboration, through an exclusive option for future licensing rights, to advance first-in-class small-molecule treatments for neuronopathic Gaucher disease (types 2 and 3).

Scenic Biotech joins MJFF LITE program to expand PLA2G15 research

Thu, 11 Jun 2026 09:00:00 -0400

Scenic Biotech BV has joined The Michael J. Fox Foundation for Parkinson’s Research (MJFF) LRRK2 Investigative Therapeutics Exchange (LITE) program to explore the therapeutic potential of its PLA2G15 inhibitor program in Parkinson’s disease, including in patients carrying LRRK2 mutations.

Syntax Bio and Mayo Clinic partner in type 1 diabetes

Wed, 10 Jun 2026 09:00:00 -0400

Syntax Bio Inc. has established a research and development collaboration with Mayo Clinic focused on advancing stem cell-derived pancreatic cell therapies for type 1 diabetes.

Arvinas joins MJFF initiatives to advance LRRK2 research

Fri, 05 Jun 2026 09:00:00 -0400

Arvinas Inc. has joined the LRRK2 Investigative Therapeutics Exchange (LITE) program and the Parkinson’s Precision Medicine Initiative (PPMI), both supported by The Michael J. Fox Foundation for Parkinson’s Research (MJFF).

Xtalpi reports milestones under Dovetree collaboration

Mon, 01 Jun 2026 09:00:00 -0400

Xtalpi Inc.’s strategic collaboration with Dovetree Medicines Unus Inc. has made substantial progress, with Xtalpi receiving the second payment under the agreement.

CEPI supports Moderna’s vaccine against Bundibugyo Ebola virus

Mon, 01 Jun 2026 09:00:00 -0400

Moderna Inc. has announced an expanded collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI) to advance the development of a potential vaccine against Bundibugyo Ebola virus (BDBV), a cause of Ebola virus disease.

Innovent, Pfizer partner on 12 early-stage cancer programs

Fri, 29 May 2026 09:00:00 -0400

Innovent Biologics Inc. and Pfizer Inc. have entered into a strategic global licensing and collaboration agreement for the research and development of 12 new breakthrough early-stage and de novo cancer medicines.

Biomunex enters AI partnerships to advance cancer immunotherapies

Wed, 27 May 2026 09:00:00 -0400

Biomunex Pharmaceuticals SAS has entered into strategic collaborations with two AI-specialized companies – Gordion Bioscience Inc. and Tangramed Biotech SAS – as part of its strategy to integrate AI into its R&D activities and support the development of next-generation immunotherapies in oncology.

Circio and Aavigen to collaborate on targeted cardiac AAVs

Wed, 27 May 2026 09:00:00 -0400

Circio Holding ASA and Aavigen GmbH have entered a research collaboration focused on developing circVec-enhanced AAV vectors engineered for targeted, low-dose gene therapies for heart diseases.

Launch of CGTxchange to reactivate cell and gene therapy programs

Fri, 15 May 2026 09:00:00 -0400

The American Society of Gene & Cell Therapy (ASGCT) and Orphan Therapeutics Accelerator (OTXL) have announced the public launch of CGTxchange, an AI-enhanced clearinghouse and marketplace built to help reactivate cell and gene therapy programs that have been shelved despite strong scientific and clinical evidence.

Andzonbio2 enters neuroinflammation collaboration

Thu, 14 May 2026 09:00:00 -0400

Andzonbio2 has signed agreements with the Alborada Drug Discovery Institute (ADDI) at the University of Cambridge and Cambridge Enterprise to advance a new class of therapeutics targeting neuroinflammation, a central driver of multiple neurodegenerative and neurological conditions.

AOP Health and VRG Therapeutics partner on immunology program

Wed, 13 May 2026 09:00:00 -0400

AOP Orphan Pharmaceuticals GmbH (AOP Health) has established a strategic partnership with VRG Therapeutics Zrt to advance a novel Kv1.3 potassium channel inhibitor for use in inflammation and immunology indications.

UCB and Cancer Research UK enter new oncology alliance

Thu, 07 May 2026 09:00:00 -0400

UCB SA has entered into a new multiproject strategic alliance with Cancer Research UK and its innovation arm, Cancer Research Horizons, to advance a pipeline of novel investigational oncology candidates.

Apertura Gene Therapy and TSC Alliance partner on gene therapies

Wed, 06 May 2026 09:00:00 -0400

Apertura Gene Therapy LLC and the TSC Alliance have established a collaboration to advance gene therapy programs designed to treat tuberous sclerosis complex (TSC).

Elaaj Bio advances gene therapy for CDKL5 deﬁciency disorder

Wed, 06 May 2026 09:00:00 -0400

Elaaj Bio, a wholly owned subsidiary of the nonproﬁt Loulou Foundation, has entered into a partnership with Viralgen Vector Core SL to advance a gene therapy program for CDKL5 deﬁciency disorder.

Genomics and Greywolf partner in autoimmune diseases

Thu, 30 Apr 2026 09:00:00 -0400

Genomics Ltd. has established a strategic relationship with Grey Wolf Therapeutics Ltd. (Greywolf) to develop first-in-class treatments for autoimmune diseases.

Astrazeneca exercises option for Pinetree’s PTX-299

Thu, 30 Apr 2026 09:00:00 -0400

Astrazeneca plc has exercised an option under its collaboration with Pinetree Therapeutics Inc. to obtain an exclusive global license to develop and commercialize PTX-299, a first-in-class bispecific antibody degrader targeting EGFR. The option exercise triggers a $25 million payment to Pinetree.

Milestone in Atrium and BMS cardiovascular collaboration

Fri, 24 Apr 2026 09:00:00 -0400

Atrium Therapeutics Inc. has earned a $15 million development milestone payment from Bristol Myers Squibb Co. (BMS) for the successful delivery of a development candidate for the first licensed compound targeting a cardiology indication under the companies’ ongoing collaboration.

Entos and L-CMD Research Foundation collaborate

Tue, 21 Apr 2026 09:00:00 -0400

Entos Pharmaceuticals Inc. has established a collaboration with the L-CMD Research Foundation with the aim of developing a curative therapy for LMNA-related congenital muscular dystrophy (L-CMD).

Biogen to use Alloy Therapeutics’ Anticlastic ASO platform

Wed, 08 Apr 2026 09:00:00 -0400

Alloy Therapeutics Inc. has entered into a collaboration and license agreement with Biogen Inc. for the use of Alloy’s Anticlastic ASO platform to accelerate the development of innovative oligonucleotide therapeutics.

Akari Therapeutics partners with Wuxi XDC on ADC payload

Tue, 07 Apr 2026 09:00:00 -0400

Akari Therapeutics plc has established a strategic partnership with Wuxi XDC Cayman Inc. to accelerate the development of Akari’s novel PH1 payload. Akari’s lead program, AKTX-101, is initially targeting metastatic urothelial cancer.

Insilico Medicine and Aska enter gynecological collaboration

Wed, 25 Mar 2026 09:00:00 -0400

Insilico Medicine Cayman Topco has established a strategic research collaboration with Aska Pharmaceutical Co. Ltd. to identify novel therapeutic targets for challenging gynecological conditions, including endometriosis, uterine fibroids and adenomyosis.

Insitro and Bristol Myers Squibb expand ALS collaboration

Tue, 24 Mar 2026 09:00:00 -0400

Insitro Inc. has expanded its strategic collaboration with Bristol Myers Squibb Co. to advance a broadened portfolio of therapeutic programs for amyotrophic lateral sclerosis (ALS).